The abundance of some common immune checkpoints (e.g., PD-1, PD-L1) varies among different pathological types, and the positive rate of PD-1/PD-L1 in uterine endometrioid carcinomas, uterine serous carcinoma, and uterine clear cell carcinoma are 40–80%, 10–68%, and 23–69%, respectively, which may affect their response to immunotherapy [17, 18]. The gene discussed is CD274; the disease is endometrial serous adenocarcinoma.